Dabigatran and myocardial infarction

Chest

Volumn 147, Issue 2, 2015, Pages e70-e71

  Hohnloser, Stefan H ^a   Lip, Gregory Y H ^b  

^a GOETHE UNIVERSITY   (Germany)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; HIRULOG; RIVAROXABAN; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; THROMBIN;

BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PROTECTION; HUMAN; INTRACARDIAC THROMBOSIS; LETTER; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; HEART DISEASES; THROMBOSIS;

ANTICOAGULANTS; HEART DISEASES; HUMANS; THROMBIN; THROMBOSIS;

EID: 84922225384     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2534     Document Type: Article

References (5)

1. Davidson BL. The association of direct thrombin inhibitor anticoag ulants with cardiac thrombosis. Chest. 2015; 147 ( 1): 21-24.
2. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fi brillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Th erapy) trial. Circulation. 2012; 125 ( 5): 669-676.
3. Larsen TB, Rasmussen LH, Skjøth F, et al. Effi cacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fi brillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013; 61 ( 22): 2264-2273.
4. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fi brillation [published online ahead of print October 30, 2014]. Circulation. doi:10. 1161/CIRCULATIONAHA. 114. 012061.
5. Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fi brillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Th rombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacifi c Heart Rhythm Society (APHRS) [published online ahead of print August 25, 2014]. Eur Heart J. doi:10. 1093/eurheartj/ehu298.